OBJECTIVE： To investigate the effects of clinical pharmacists on the treatment for muscle stiffness followed by dyspnea induced by Fentanyl transdermal patch. METHODS： Clinical pharmacists participated in drug treatment for a patient with advanced prostate cancer complicating with severe pain. Through analyzing medication history， combined with the characteristics of pharmacological action and ADR， clinical pharmacists assisted physicians to identify and analyze the risk of muscle stiffness followed by dyspnea induced by Fentanyl transdermal patch. According to symptoms， clinical pharmacists suggested not stopping using Fentanyl transdermal patch， using muscle relaxant Eperisone hydrochloride tablets 50 mg，po，tid to relieve muscle stiffness， and stopping using Lorazepam tablets， Haloperidol tablets and Diphenhydramine hydrochloride tablets so as to reduce the risk factor of delirium. RESULTS： Physicians adopted the suggestions of clinical pharmacists. The chest wall muscles stiffness and dyspnea were relieved， and the pain could be controlled. The patient was discharged from the hospital with medicine on the 12th day. CONCLUSIONS： The muscle stiffness followed by dyspnea induced by Fentanyl transdermal patch is easily confused with respiratory central inhibition. Clinical pharmacists and physicians should be identify them timely and dispose it properly.